More Breast Cancer Patients Could Benefit From PARP Inhibitors

Cancer - United States
doi 10.1002/cncr.30962
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Wiley

Related search

CXCR4 Inhibitors Could Benefit to HER2 but Not to Triple-Negative Breast Cancer Patients

Oncogene
Cancer ResearchGeneticsMolecular Biology
2016English

PARP Inhibitors: Extending Benefit Beyond BRCA Mutant Cancers

Clinical Cancer Research
Cancer ResearchOncology
2019English

PARP Inhibitors in Ovarian Cancer

2013English

Inhibitors Targeting CDK4/6, PARP and PI3K in Breast Cancer: A Review

Therapeutic Advances in Medical Oncology
Oncology
2018English

The Development of PARP Inhibitors in Ovarian Cancer: From Bench to Bedside

British Journal of Cancer
Cancer ResearchOncology
2015English

PARP Inhibitors and Stratified Treatment of Prostate Cancer

Expert Review of Anticancer Therapy
OncologyPharmacology
2016English

The Inhibition and Treatment of Breast Cancer With Poly (ADP-ribose) Polymerase (PARP-1) Inhibitors

International Journal of Biological Sciences
Applied MicrobiologyEvolutionEcologyDevelopmental BiologyCell BiologyMolecular BiologySystematicsBehaviorBiotechnology
2006English

PARP Inhibitors in Cancer Therapy: Promise, Progress, and Puzzles

Cancer Cell
Cancer ResearchOncologyCell Biology
2011English

Extending the Scope of PARP Inhibitors in Ovarian Cancer

The Lancet Oncology
Oncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy